Juan Luis Rodriguez Hermosa
Overview
Explore the profile of Juan Luis Rodriguez Hermosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calle Rubio M, Adami Teppa P, Rodriguez Hermosa J, Garcia Carro M, Tallon Martinez J, Riesco Rubio C, et al.
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004748
Despite the ongoing innovations and the availability of numerous effective inhaled treatment options, achieving optimal disease control in most patients frequently remains disappointing. Unfortunately, although inhaled therapy is the cornerstone...
2.
Calle Rubio M, Cebollero Rivas P, Esteban C, Fuster Gomila A, Garcia Guerra J, Golpe R, et al.
Healthcare (Basel)
. 2025 Feb;
13(3).
PMID: 39942506
Chronic obstructive pulmonary disease (COPD) represents one of the most frequent causes of hospital readmissions and in-hospital mortality. One in five patients requires readmission within 30 days of discharge following...
3.
Calle Rubio M, Cataluna J, Miravitlles M, Navarrete B, Lopez-Campos J, Ferrer M, et al.
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941377
: the concept of clinical control of COPD is a measure proposed in the Spanish COPD Guidelines (GesEPOC), which aims to help clinicians assess the clinical status in order to...
4.
Calle Rubio M, Miravitlles M, Cataluna J, Lopez-Campos J, Navarrete B, Ferrer M, et al.
PLoS One
. 2025 Jan;
20(1):e0314299.
PMID: 39787174
Objective: This study aimed to evaluate clinical control in chronic obstructive pulmonary disease (COPD), the consequences in terms of treatment decisions, and their potentially associated factors during follow-up of patients...
5.
Calle Rubio M, Miravitlles M, Lopez-Campos J, Soler-Cataluna J, Navarrete B, Fuentes-Ferrer M, et al.
J Clin Med
. 2024 Feb;
13(4).
PMID: 38398268
Background: Alpha-1 antitrypsin deficiency (AATD) is an underdiagnosed condition despite being one of the most common inherited disorders in adults that is associated with an increased risk of developing chronic...
6.
Gonzalez-Jimenez P, Mengot N, Ruiz L, Serrano L, Espana P, Cilloniz C, et al.
Front Med (Lausanne)
. 2023 Oct;
10:1236142.
PMID: 37886363
Introduction: There are no data on the association of type of pneumonia and long-term mortality by the type of pneumonia (COVID-19 or community-acquired pneumonia [CAP]) on long-term mortality after an...
7.
Calle Rubio M, Miravitlles M, Lopez-Campos J, Navarrete B, Cataluna J, Ferrer M, et al.
Arch Bronconeumol
. 2023 Aug;
59(11):725-735.
PMID: 37563018
Objective: The aim of this analysis was to describe the patterns of inhaled maintenance therapy according to risk level and to explore the determinants associated with the decision to prescribe...
8.
Rodriguez Hermosa J, Miravitlles M, Lopez-Campos J, Calle Rubio M
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445508
Background: The objective of this analysis is to evaluate tobacco use and the level of chronic obstructive pulmonary disease (COPD) knowledge among the general adult population in Spain and to...
9.
Calle Rubio M, Lopez-Campos J, Miravitlles M, Cataluna J, Navarrete B, Ferrer M, et al.
Arch Bronconeumol
. 2023 Mar;
59(5):295-304.
PMID: 36858911
Introduction: The aim of our work has been to describe the results of the clinical audit carried out in 2021 and to compare the results with 2015 EPOCONSUL audit. Methods:...
10.
Rodriguez Hermosa J, Vargas Centanaro G, Estela Gonzalez Castro M, Miravitlles M, Lazaro-Asegurado L, Jimenez-Rodriguez B, et al.
Biomedicines
. 2023 Feb;
11(2).
PMID: 36831051
Background: Epidemiologic studies have reported that the geographical distribution of the prevalence of allelic variants of serine protein inhibitor-A1 (SERPINA1) and severe cases of COVID-19 were similar. Methods: A multicenter,...